Pig & Poultry Vaccines

For active immunisation of chicks to reduce clinical signs, intestinal lesions and oocysts output of Coccidiosis caused by Eimeria acervulina, Eimeria brunetti, Eimeria maxima, Eimeria necatrix and Eimeria tenella. Onset of immunity: 3 weeks post-vaccination. Duration of immunity: 60 weeks post-vaccination. One dose of vaccine from 1 day of age by coarse spray

Chickens(Broilers) : For active immunisation of broilers with insigni cant levels of maternally derived antibodies (ELISA of 500 or below) to reduce mortality, clinical signs and bursal lesions of Gumboro disease. Such birds can be vaccinated from one day of age. The onset of immunity is 14 days post vaccination and the duration 43 days post vaccination. DOSAGE, ROUTE AND METHOD OF ADMINISTRATION: Dosage: 1 dose/bird. Administration route: Oral. Break the vacuum inside the vial by inoculation of 10 ml of drinking water without chlorine or disinfectants. Shake gently until complete resuspension of the freeze-dried powder before administration

HYOGEN® is the unique inactivated vaccine that offers strong fast and long lasting protection by using just ONE dose (2 ml) in the life time of market pigs. This is due to its main components; the antigen originated from Ceva M. hyo strain BA 2940-99 along with the adjuvant, ImuvantTM. ImuvantTM is a unique Ceva adjuvant composed of a non-toxic lipopolysaccharide (LPS) from J5 E. coli together with a mineral oil in water emulsion that forms a complex and highly efficient immunostimulant. These components and balance formulation will enable and appropriate innate, humoral and cell-mediated immune response from the host. Hyogen® provides active immunisation of healthy pigs against Mycoplasma hyopneumoniae INDICATIONS Active immunization of healthy pigs against enzootic pneumonia caused by Mycoplasma hyopneumoniae in herds where the chronic or acute disease causes losses. ADMINISTRATION AND DOSAGE Intramuscularly. Inject ONE dose (2 ml) from 3 weeks of age onwards.

For rinsing Idal intradermal needleless vaccinators

For active immunisation of pigs over the age of 2 weeks against porcine circovirus Type 2 (PCV2) to reduce mortality, clinical signs - including weight loss - and lesions in lymphoid tissues associated with PCV2 related diseases (PCVD). In addition, vaccination has been shown to reduced PCV2 nasal shedding, viral load in blood and lymphoid tissues, and duration of viraemia.

For active immunisation of pigs over the age of 2 weeks against porcine circovirus Type 2 (PCV2) to reduce mortality, clinical signs - including weight loss - and lesions in lymphoid tissues associated with PCV2 related diseases (PCVD). In addition, vaccination has been shown to reduced PCV2 nasal shedding, viral load in blood and lymphoid tissues, and duration of viraemia.

Live, freeze-dried vaccine aganist avian rhinotraceheitis. Each dose of vaccine contains at least 101.5-3.7 TCID50 avian rhinotraceheitis vaccine virus. The vaccine pellet contains stabilizers.

M+PAC is for the active immunisation of pigs from 7 days of age against infection caused by Mycoplasma hyopneumoniae.

M+PAC is for the active immunisation of pigs from 7 days of age against infection caused by Mycoplasma hyopneumoniae.

Intradermal needle-free vaccine against Mycoplasma hyopneumoniae and PCV2, all in one, in suspension for injection For the active immunisation of pigs: - to reduce lung lesions associated with porcine enzootic pneumonia caused by Mycoplasma hyopneumoniae. Also, to reduce the incidence of these lesions (as observed in field studies). - to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by Porcine circovirus type 2 PCV2. Efficacy against PCV2 genotypes a, b and d has been demonstrated in field studies. - to reduce culling rate and the loss of daily weight gain caused by Mycoplasma hyopneumoniae and/or PCV2 related diseases (as observed at 6 months of age in field studies). Mycoplasma hyopneumoniae: Onset of immunity: 3 weeks after vaccination. Duration of immunity: 23 weeks after vaccination. Porcine circovirus type 2: Onset of immunity: 2 weeks after vaccination. Duration of immunity: 22 weeks after vaccination. In addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of PCV2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION: For intradermal use. Administer one dose of 0.2 ml to pigs from 3 weeks of age onwards by intradermal administration at the sides of the neck using a suitable needle-free device able to administer 0.2 ml doses per shot (with an injection stream diameter of 0.25-0.30 mm and a peak force of injection of 0.9-1.3 N).

Intradermal needle-free vaccine against Mycoplasma hyopneumoniae and PCV2, all in one, in suspension for injection For the active immunisation of pigs: - to reduce lung lesions associated with porcine enzootic pneumonia caused by Mycoplasma hyopneumoniae. Also, to reduce the incidence of these lesions (as observed in field studies). - to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by Porcine circovirus type 2 PCV2. Efficacy against PCV2 genotypes a, b and d has been demonstrated in field studies. - to reduce culling rate and the loss of daily weight gain caused by Mycoplasma hyopneumoniae and/or PCV2 related diseases (as observed at 6 months of age in field studies). Mycoplasma hyopneumoniae: Onset of immunity: 3 weeks after vaccination. Duration of immunity: 23 weeks after vaccination. Porcine circovirus type 2: Onset of immunity: 2 weeks after vaccination. Duration of immunity: 22 weeks after vaccination. In addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of PCV2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION: For intradermal use. Administer one dose of 0.2 ml to pigs from 3 weeks of age onwards by intradermal administration at the sides of the neck using a suitable needle-free device able to administer 0.2 ml doses per shot (with an injection stream diameter of 0.25-0.30 mm and a peak force of injection of 0.9-1.3 N).

Nobilis CAV P4 is a live attenuated vaccine against Chicken Anaemia Virus. Indications Vaccination of chickens against chicken anaemia from 6 weeks of age onwards until 6 weeks prior to the onset of lay. Vaccination The vaccine can be administered to chickens from 6 weeks of age onwards. To make sure that adequate antibody levels are present before laying commences, breeding stock needs to be vaccinated at least 6 weeks before the onset of lay. Vaccination against CAV can be combined with vaccination against Reo-live or inactivated viral vaccines (intramuscular or subcutaneous route) or with vaccination against Fowl Pox (wingweb route) or with vaccination with Nobilis AE + Pox. Dosage 0.2 ml per bird. Method of administration For intramuscular or subcutaneous injection: • Reconstitute the vaccine in Intervet’s diluent Dilavia, using 200 ml per 1000 doses. • Administer 0.2 ml of the vaccine by intramuscular or subcutaneous injection. For the wingweb method: • Reconstitute the vaccine in Intervet’s diluent Unisolve, using 13 ml per 1000 doses. o Dip the double needle into the vaccine solution so that both grooves are filled, before vaccinating each bird. • Insert the needle through the wingweb from beneath. For use with inactivated vaccines: • Reconstitute the vaccine in 2 ml of Sterile Phosphate Buffered Saline and add this to the inactivated viral vaccine, shake the vaccine well before use. Withholding period None.